In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer
- PMID: 10992180
- DOI: 10.1067/mob.2000.107097
In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer
Abstract
Objective: The purpose of this study was to evaluate the potential of dendritic cells pulsed with whole-tumor extracts derived from autologous ovarian cancer cells in eliciting a tumor-specific cytotoxic T-cell response in vitro from patients with advanced ovarian cancer.
Study design: CD8(+) T lymphocytes stimulated in vitro with autologous ovarian tumor lysate-pulsed dendritic cells were tested for their ability to induce a human leukocyte antigen class I-restricted cytotoxic T-lymphocyte response able to specifically kill autologous tumor cells in standard 6-hour chromium 51 cytotoxicity assays. In addition, to correlate cytotoxic activity by cytotoxic T-lymphocytes with a particular lymphoid subset, 2-color flow cytometric analysis of intracellular cytokine expression (interferon gamma and interleukin 4) at the single-cell level was performed.
Results: Cytotoxic T lymphocytes specific for autologous ovarian tumor cells were elicited from 3 patients with advanced ovarian cancer. Although cytotoxic T-lymphocyte populations expressed strong cytolytic activity against autologous tumor cells, they did not lyse concanavalin A-stimulated autologous lymphocytes or autologous Epstein-Barr virus-transformed lymphoblastoid cell lines and showed negligible cytotoxicity against the natural killer cell-sensitive cell line K-562. Cytotoxic effect against the autologous tumor cells was inhibited by an anti-human leukocyte antigen class I monoclonal antibody (W6/32). It is interesting that CD8(+) cytotoxic T lymphocytes expressed variable levels of CD56, a marker that may be associated with high cytotoxic activity. Finally, most of the tumor-specific CD8(+) T cells exhibited a T(H)1 cytokine bias, and a high percentage of interferon gamma expressors among cytotoxic T lymphocytes was correlated with higher cytotoxic activity.
Conclusion: These data show that tumor lysate-pulsed dendritic cells can consistently induce in vitro specific CD8(+) cytotoxic T lymphocytes able to kill autologous tumor cells from patients with advanced stage ovarian cancer. This novel approach may have important implications for the treatment of residual or resistant disease with active or adoptive immunotherapy after standard surgical and cytotoxic treatment.
Similar articles
-
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048. Cancer. 2009. PMID: 19117353
-
Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.Obstet Gynecol. 2000 Sep;96(3):422-30. doi: 10.1016/s0029-7844(00)00916-9. Obstet Gynecol. 2000. PMID: 10960637
-
Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.Clin Cancer Res. 2001 Mar;7(3 Suppl):804s-810s. Clin Cancer Res. 2001. PMID: 11300476
-
[Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].Zentralbl Chir. 1997;122(3):141-8. Zentralbl Chir. 1997. PMID: 9206906 Review. German.
-
Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.Semin Cancer Biol. 1991 Oct;2(5):347-54. Semin Cancer Biol. 1991. PMID: 1773050 Review.
Cited by
-
A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade.J Transl Med. 2019 Dec 19;17(1):424. doi: 10.1186/s12967-019-02163-4. J Transl Med. 2019. PMID: 31878933 Free PMC article.
-
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.Br J Cancer. 2004 May 4;90(9):1814-24. doi: 10.1038/sj.bjc.6601791. Br J Cancer. 2004. PMID: 15208622 Free PMC article.
-
Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.Am J Reprod Immunol. 2011 Jun;65(6):597-609. doi: 10.1111/j.1600-0897.2010.00968.x. Epub 2011 Jan 18. Am J Reprod Immunol. 2011. PMID: 21241402 Free PMC article.
-
Second-line and subsequent therapy for ovarian carcinoma.Curr Oncol Rep. 2002 Mar;4(2):159-64. doi: 10.1007/s11912-002-0077-0. Curr Oncol Rep. 2002. PMID: 11822988 Review.
-
Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.Cancer Immunol Immunother. 2004 Jun;53(6):560-6. doi: 10.1007/s00262-004-0502-3. Epub 2004 Feb 25. Cancer Immunol Immunother. 2004. PMID: 14985861 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials